[go: up one dir, main page]

HK1183615B - Combination of a pyrroloquinoline compound and an aminoglycodise antimicrobial agent - Google Patents

Combination of a pyrroloquinoline compound and an aminoglycodise antimicrobial agent

Info

Publication number
HK1183615B
HK1183615B HK13110275.0A HK13110275A HK1183615B HK 1183615 B HK1183615 B HK 1183615B HK 13110275 A HK13110275 A HK 13110275A HK 1183615 B HK1183615 B HK 1183615B
Authority
HK
Hong Kong
Prior art keywords
infections
pharmaceutically acceptable
solvate
combination
acceptable salt
Prior art date
Application number
HK13110275.0A
Other languages
German (de)
French (fr)
Chinese (zh)
Other versions
HK1183615A (en
Inventor
Hu Yanmin
R. M. COATES Anthony
Original Assignee
Helperby Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helperby Therapeutics Limited filed Critical Helperby Therapeutics Limited
Publication of HK1183615A publication Critical patent/HK1183615A/en
Publication of HK1183615B publication Critical patent/HK1183615B/en

Links

Description

This invention relates to a combination of antimicrobial agents which are useful for the prevention and/or treatment of microbial infections. In particular, it relates to a combination comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable salt and/or solvate thereof and an aminoglycoside antimicrobial agent or a pharmaceutically acceptable salt and/or solvate thereof, wherein the aminoglycoside antimicrobial agent is selected from the group consisting of arbekacin, amikacin, apramycin, gentamicin, netilmicin, neomycin, streptomycin, tobramycin, amastatin, butirosin, butirosin A, daunorubicin, dibekacin, dihydrostreptomycin, G 418, hygromycin B, kanamycin B, kanamycin, kirromycin, paromomycin, rhodostreptomycin, ribostamycin, sisomicin, spectinomycin, streptozocin and thiostrepton, or a pharmaceutically acceptable salt and/or solvate thereof. This combination is particularly useful for the prevention and/or treatment of a bacterial infection caused by Staphylococcus aureus or Pseudomonas aeruginosa.
Before the introduction of antibiotics, patients suffering from acute microbial infections (e.g. tuberculosis or pneumonia) had a low chance of survival. For example, mortality from tuberculosis was around 50%. Although the introduction of antimicrobial agents in the 1940s and 1950s rapidly changed this picture, bacteria have responded by progressively gaining resistance to commonly used antibiotics. Now, every country in the world has antibioticresistant bacteria. Indeed, more than 70% of bacteria that give rise to hospital acquired infections in the USA resist at least one of the main antimicrobial agents that are typically used to fight infection ( Nature Reviews, Drug Discovery 1, 895-910 (2002)).
One way of tackling the growing problem of resistant bacteria is the development of new classes of antimicrobial agents. However, until the introduction of linezolid in 2000, there had been no new class of antibiotic marketed for over 37 years. Moreover, even the development of new classes of antibiotic provides only a temporary solution, and indeed there are already reports of resistance of certain bacteria to linezolid ( Lancet 357, 1179 (2001) and Lancet 358, 207-208 (2001)).
In order to develop more long-term solutions to the problem of bacterial resistance, it is clear that alternative approaches are required. One such alternative approach is to minimise, as much as is possible, the opportunities that bacteria are given for developing resistance to important antibiotics. Thus, strategies that can be adopted include limiting the use of antibiotics for the treatment of non-acute infections, as well as controlling which antibiotics are fed to animals in order to promote growth.
However, in order to tackle the problem more effectively, it is necessary to gain an understanding of the actual mechanisms by which bacteria generate resistance to antibiotic agents. To do this requires first a consideration of how current antibiotic agents work to kill bacteria.
Antimicrobial agents target essential components of bacterial metabolism. For example, the β-lactams (e.g. penicillins and cephalosporins) inhibit cell wall synthesis, whereas other agents inhibit a diverse range of targets, such as DNA gyrase (quinolones) and protein synthesis (e.g. macrolides, aminoglycosides, tetracyclines and oxazolidinones). The range of organisms against which the antimicrobial agents are effective varies, depending upon which organisms are heavily reliant upon the metabolic step(s) that is/are inhibited. Further, the effect upon bacteria can vary from a mere inhibition of growth (i.e. a bacteriostatic effect, as seen with agents such as the tetracyclines) to full killing (i.e. a bactericidal effect, as seen, e.g. with penicillin).
Bacteria have been growing on Earth for more than 3 billion years and, in that time, have needed to respond to vast numbers of environmental stresses. It is therefore perhaps not surprising that bacteria have developed a seemingly inexhaustible variety of mechanisms by which they can respond to the metabolic stresses imposed upon them by antibiotic agents. Indeed, mechanisms by which the bacteria can generate resistance include strategies as diverse as inactivation of the drug, modification of the site of action, modification of the permeability of the cell wall, overproduction of the target enzyme and bypass of the inhibited steps. Nevertheless, the rate of resistance emerges to a particular agent has been observed to vary widely, depending upon factors such as the agent's mechanism of action, whether the agent's mode of killing is time- or concentration-dependent, the potency against the population of bacteria and the magnitude and duration of the available serum concentration.
It has been proposed ( Science 264, 388-393 (1994)) that agents that target single enzymes (e.g. rifampicin) are the most prone to the development of resistance. Further, the longer that suboptimal levels of antimicrobial agent are in contact with the bacteria, the more likely the emergence of resistance.
Moreover, it is now known that many microbial infections include sub-populations of bacteria that are phenotypically resistant to antimicrobials ( J. Antimicrob. Chemother. 4, 395-404 (1988); J. Med. Microbiol. 38, 197-202 (1993); J. Bacteriol. 182, 1794-1801 (2000); ibid. 182, 6358-6365 (2000); ibid. 183, 6746-6751 (2001); FEMS Microbiol. Lett. 202, 59-65 (2001); and Trends in Microbiology 13, 34-40 (2005)). There appear to be several types of such phenotypically resistant bacteria, including persisters, stationary-phase bacteria, as well as those in the depths of biofilms. However, each of these types is characterised by its low rate of growth compared to log-phase bacteria under the same conditions. Nutritional starvation and high cell densities are also common characteristics of such bacteria.
Although resistant to antimicrobial agents in their slow-growing state, phenotypically resistant bacteria differ from those that are genotypically resistant in that they regain their susceptibility to antimicrobials when they return to a fast-growing state (e.g. when nutrients become more readily available to them).
The presence of phenotypically resistant bacteria in an infection leads to the need for prolonged courses of antimicrobial agents, comprising multiple doses. This is because the resistant, slowly multiplying bacteria provide a pool of "latent" organisms that can convert to a fast-growing state when the conditions allow (thereby effectively re-initiating the infection). Multiple doses over time deal with this issue by gradually killing off the "latent" bacteria that convert to "active" form.
However, dealing with "latent" bacteria by administering prolonged courses of antimicrobials poses its own problems. That is, prolonged exposure of bacteria to suboptimal concentrations of antimicrobial agent can lead to the emergence of genotypically resistant bacteria, which can then multiply rapidly in the presence of even high concentrations of the antimicrobial.
Long courses of antimicrobials are more likely to encourage the emergence of genotypic resistance than shorter courses on the grounds that non-multiplying bacterial will tend to survive and, interestingly, probably have an enhanced ability to mutate to resistance ( Proc. Natl. Acad. Sci. USA 92, 11736-11740 (1995); J. Bacteriol. 179, 6688-6691 (1997); and Antimicrob. Agents Chemother. 44, 1771-1777 (2000)).
In the light of the above, a new approach to combating the problem of bacterial resistance might be to select and develop antimicrobial agents on the basis of their ability to kill "latent" microorganisms. The production of such agents would allow, amongst other things, for the shortening of chemotherapy regimes in the treatment of microbial infections, thus reducing the frequency with which genotypical resistance arises in microorganisms.
International Patent Application, Publication Number WO2000028074 describes a method of screening compounds to determine their ability to kill clinically latent microorganisms. Using this method, the Applicant has observed that many conventional antimicrobial agents, such as co-amoxiclav, azithromycin, levofloxacin, linezolid and mupirocin, which otherwise exhibit excellent biological activity against log phase (i.e. multiplying) bacteria, exhibit little or no activity against clinically latent microorganisms. This observation has necessitated the development of novel antimicrobials which may be used to kill clinically latent microorganisms.
International Patent Application, Publication Numbers WO2007054693 , WO2008117079 and WO2008142384 describe compounds which exhibit biological activity against clinically latent microorganisms. Examples of such compounds include 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline, 4-(3-benzylpyrrolidin-1-yl)-2-methyl-6-phenoxyquinoline, N-[4-(3-benzylpyrrolidin-1-yl)-2-methylquinolin-6-yl]benzamide and pharmaceutically acceptable derivatives thereof.
International Patent Application WO2008056151 describes pharmaceutical formulations for topical application comprising compounds based upon the pyrrole[3,2-c]quinoline ring system. One such compound is 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline.
A variety of aminoglycoside antimicrobial agents are known. Examples include amikacin, gentamicin, netilmicin, neomycin, streptomycin, tobramycin, amastatin, butirosin, butirosin A, daunorubicin, dibekacin, dihydrostreptomycin, G 418, hygromycin B, kanamycin B, kanamycin, kirromycin, paromomycin, ribostamycin, sisomicin, spectinomycin, streptozocin and thiostrepton.
The present invention is based upon the unexpected finding that the antimicrobial activity of an aminoglycoside antimicrobial agent is substantially improved if it is administered in combination with the compound 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline. Moreover, this combination of agents has surprisingly been shown to exhibit synergistic antimicrobial activity against certain log phase (i.e. multiplying) and stationary phase (i.e. non-multiplying) microorganisms. The surprising biological activity of the combination of the present invention offers the opportunity to shorten chemotherapy regimes and may result in a reduction in the emergence of microbial resistance associated with the use of such a combination.
Thus, in one embodiment the present invention provides a combination comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable salt and/or solvate thereof and an aminoglycoside antimicrobial agent or a pharmaceutically acceptable salt and/or solvate thereof, wherein the aminoglycoside antimicrobial agent is selected from the group consisting of arbekacin, amikacin, apramycin, gentamicin, netilmicin, neomycin, streptomycin, tobramycin, amastatin, butirosin, butirosin A, daunorubicin, dibekacin, dihydrostreptomycin, G 418, hygromycin B, kanamycin B, kanamycin, kirromycin, paromomycin, rhodostreptomycin, ribostamycin, sisomicin, spectinomycin, streptozocin and thiostrepton, or a pharmaceutically acceptable salt and/or solvate thereof.
In another embodiment, the invention provides the combination of the invention for use in the prevention and/or treatment of a bacterial infection, wherein the bacterial infection is caused by Staphylococcus aureus or Pseudomonas aeruginosa; in particular for killing multiplying, non-multiplying and/or clinically latent bacteria associated with such an infection.
As used herein, the terms "combination" and "in combination with" refer to both separate and sequential administration of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable salt and/or solvate thereof and the aminoglycoside antimicrobial agent or a pharmaceutically acceptable salt and/or solvate thereof. When the agents are administered sequentially, either 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable salt and/or solvate thereof, or the aminoglycoside antimicrobial agent or a pharmaceutically acceptable salt and/or solvate thereof may be administered first. When administration is simultaneous, the agents may be administered either in the same or a different pharmaceutical composition. Adjunctive therapy, i.e. where one agent is used as a primary treatment and the other agent is used to assist that primary treatment, is also an embodiment of the present invention.
According to a further embodiment of the invention, there is provided a product comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable salt and/or solvate thereof and an aminoglycoside antimicrobial agent or a pharmaceutically acceptable salt and/or solvate thereof as a combined preparation for simultaneous, separate or sequential use in the prevention and/or treatment of a bacterial infection, wherein the infection is caused by Staphylococcus aureus or Pseudomonas aeruginosa, wherein the aminoglycoside antimicrobial agent is selected from the group consisting of arbekacin, amikacin, apramycin, gentamicin, netilmicin, neomycin, streptomycin, tobramycin, amastatin, butirosin, butirosin A, daunorubicin, dibekacin, dihydrostreptomycin, G 418, hygromycin B, kanamycin B, kanamycin, kirromycin, paromomycin, rhodostreptomycin, ribostamycin, sisomicin, spectinomycin, streptozocin and thiostrepton, or a pharmaceutically acceptable salt and/or solvate thereof, in particular for use in killing multiplying, non-multiplying and/or clinically latent bacteria associated with such an infection.
There is also provided a pharmaceutical composition comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable salt and/or solvate thereof, an aminoglycoside antimicrobial agent or a pharmaceutically acceptable salt and/or solvate thereof and a pharmaceutically acceptable adjuvant, diluent or carrier, wherein the aminoglycoside antimicrobial agent is selected from the group consisting of arbekacin, amikacin, apramycin, gentamicin, netilmicin, neomycin, streptomycin, tobramycin, amastatin, butirosin, butirosin A, daunorubicin, dibekacin, dihydrostreptomycin, G 418, hygromycin B, kanamycin B, kanamycin, kirromycin, paromomycin, rhodostreptomycin, ribostamycin, sisomicin, spectinomycin, streptozocin and thiostrepton, or a pharmaceutically acceptable salt and/or solvate thereof. Such a composition may be used for the prevention and/or treatment of bacterial infections, wherein the infection is caused by Staphylococcus aureus or Pseudomonas aeruginosa, and in particular for use in killing multiplying, non-multiplying and/or clinically latent bacteria associated with such an infection.
The combination of the present invention may be used to prevent and/or to treat bacterial infections caused by Staphylococcus aureus or Pseudomonas aeruginosa. In particular it may be used to kill multiplying, non-multiplying and/or clinically latent bacteria associated with such infections. References herein to the treatment of a bacterial infection therefore include killing multiplying, non-multiplying and/or clinically latent bacteria associated with such infections.
Suitable aminoglycoside antimicrobial agents for use in the combinations of the present invention include one or more agents selected form the group consisting of arbekacin, amikacin, apramycin, gentamicin, netilmicin, neomycin, streptomycin, tobramycin, amastatin, butirosin, butirosin A, daunorubicin, dibekacin, dihydrostreptomycin, G 418, hygromycin B, kanamycin B, kanamycin, kirromycin, paromomycin, rhodostreptomycin, ribostamycin, sisomicin, spectinomycin, streptozocin and thiostrepton, and pharmaceutically acceptable salt and/or solvates thereof.
Preferred aminoglycoside antimicrobial agents are kanamycin, gentamicin, tobramycin and neomycin, and pharmaceutically acceptable salts and/or solvates thereof. In one embodiment of the invention, the aminoglycoside antimicrobial agent is gentamicin or a pharmaceutically acceptable salt and/or solvate thereof. In an alternative embodiment of the invention, the aminoglycoside antimicrobial agent is neomycin or a pharmaceutically acceptable salt and/or solvate thereof. In a further alternative embodiment of the invention, the aminoglycoside antimicrobial agent is kanamycin or a pharmaceutically acceptable salt and/or solvate thereof. In still a further alternative embodiment of the invention, the aminoglycoside antimicrobial agent is tobramycin or a pharmaceutically acceptable salt and/or solvate thereof.
As used herein, "kill" means a loss of viability as assessed by a lack of metabolic activity.
As used herein, "clinically latent microorganism" means a microorganism (e.g. bacterium or bacteria) that is metabolically active but has a growth rate that is below the threshold of infectious disease expression. The threshold of infectious disease expression refers to the growth rate threshold below which symptoms of infectious disease in a host are absent.
The metabolic activity of clinically latent microorganisms can be determined by several methods known to those skilled in the art; for example, by measuring mRNA levels in the microorganisms or by determining their rate of uridine uptake. In this respect, clinically latent microorganisms, when compared to microorganisms under logarithmic growth conditions (in vitro or in vivo), possess reduced but still significant levels of:
  1. (I) mRNA (e.g. from 0.0001 to 50%, such as from 1 to 30, 5 to 25 or 10 to 20%, of the level of mRNA); and/or
  2. (II) uridine (e.g. [3H]uridine) uptake (e.g. from 0.0005 to 50%, such as from 1 to 40, 15 to 35 or 20 to 30% of the level of [3H]uridine uptake).
Clinically latent microorganisms typically possess a number of identifiable characteristics. For example, they may be viable but non-culturable; i.e. they cannot typically be detected by standard culture techniques, but are detectable and quantifiable by techniques such as broth dilution counting, microscopy, or molecular techniques such as polymerase chain reaction. In addition, clinically latent microorganisms are phenotypically tolerant, and as such are sensitive (in log phase) to the biostatic effects of conventional antimicrobial agents (i.e. microorganisms for which the minimum inhibitory concentration (MIC) of a conventional antimicrobial is substantially unchanged); but possess drastically decreased susceptibility to drug-induced killing (e.g. microorganisms for which, with any given conventional antimicrobial agent, the ratio of minimum microbiocidal concentration (e.g. minimum bactericidal concentration, MBC) to MIC is 10 or more).
As used herein, the term "microorganisms" means fungi and bacteria. References herein to "microbial", "antimicrobial" and "antimicrobially" shall be interpreted accordingly. For example, the term "microbial" means fungal or bacterial, and "microbial infection" means any fungal or bacterial infection.
As used herein, the term "bacteria" (and derivatives thereof, such as "microbial infection") includes, but is not limited to, references to organisms (or infections due to organisms) of the following classes and specific types:
  • Gram-positive cocci, such as Staphylococci (e.g. Staph. aureus, Staph. epidermidis, Staph. saprophyticus, Staph. auricularis, Staph. capitis capitis, Staph. c. ureolyticus, Staph. caprae, Staph. cohnii cohnii, Staph. c. urealyticus, Staph. equorum, Staph. gallinarum, Staph. haemolyticus, Staph. hominis hominis, Staph. h. novobiosepticius, Staph. hyicus, Staph. intermedius, Staph. lugdunensis, Staph. pasteuri, Staph. saccharolyticus, Staph. schleiferi schleiferi, Staph. s. coagulans, Staph. sciuri, Staph. simulans, Staph. warneri and Staph. xylosus);
  • Streptococci (e.g.beta-haemolytic, pyogenic streptococci (such as Strept. agalactiae, Strept. canis, Strept. dysgalactiae dysgalactiae, Strept. dysgalactiae equisimilis, Strept. equi equi, Strept. equi zooepidemicus, Strept. iniae, Strept. porcinus and Strept. pyogenes), microaerophilic, pyogenic streptococci (Streptococcus "milleri", such as Strept. anginosus, Strept. constellatus constellatus, Strept. constellatus pharyngidis and Strept. intermedius), oral streptococci of the "mitis" (alpha-haemolytic - Streptococcus "viridans", such as Strept. mitis, Strept. oralis, Strept. sanguinis, Strept. cristatus, Strept. gordonii and Strept. parasanguinis), "salivarius" (non-haemolytic, such as Strept. salivarius and Strept. vestibularis) and "mutans" (tooth-surface streptococci, such as Strept. criceti, Strept. mutans, Strept. ratti and Strept. sobrinus) groups, Strept. acidominimus, Strept. bovis, Strept. faecalis, Strept. equinus, Strept. pneumoniae and Strept. suis, or Streptococci alternatively classified as Group A, B, C, D, E, G, L, P, U or V Streptococcus);
  • Gram-negative cocci, such as Neisseria gonorrhoeae, Neisseria meningitidis, Neisseria cinerea, Neisseria elongata, Neisseria flavescens, Neisseria lactamica, Neisseria mucosa, Neisseria sicca, Neisseria subflava and Neisseria weaveri;
  • Bacillaceae, such as Bacillus anthracis, Bacillus subtilis, Bacillus thuringiensis, Bacillus stearothermophilus and Bacillus cereus;
  • Enterobacteriaceae, such as Escherichia coli, Enterobacter (e.g. Enterobacter aerogenes, Enterobacter agglomerans and Enterobacter cloacae), Citrobacter (such as Citrob. freundii and Citrob. divernis), Hafnia (e.g. Hafnia alvei), Erwinia (e.g. Erwinia persicinus), Morganella morganii, Salmonella (Salmonella enterica and Salmonella typhi), Shigella (e.g. Shigella dysenteriae, Shigella flexneri, Shigella boydii and Shigella sonnei), Klebsiella (e.g. Klebs. pneumoniae, Klebs. oxytoca, Klebs. ornitholytica, Klebs. planticola, Klebs. ozaenae, Klebs. terrigena, Klebs. granulomatis (Calymmatobacterium granulomatis) and Klebs. rhinoscleromatis), Proteus (e.g. Pr. mirabilis, Pr. rettgeri and Pr. vulgaris), Providencia (e.g. Providencia alcalifaciens, Providencia rettgeri and Providencia stuartii), Serratia (e.g. Serratia marcescens and Serratia liquifaciens), and Yersinia (e.g. Yersinia enterocolitica, Yersinia pestis and Yersinia pseudotuberculosis);
  • Enterococci (e.g. Enterococcus avium, Enterococcus casseliflavus, Enterococcus cecorum, Enterococcus dispar, Enterococcus durans, Enterococcus faecalis, Enterococcus faecium, Enterococcus flavescens, Enterococcus gallinarum, Enterococcus hirae, Enterococcus malodoratus, Enterococcus mundtii, Enterococcus pseudoavium, Enterococcus raffinosus and Enterococcus solitarius);
  • Helicobacter (e.g. Helicobacter pylori, Helicobacter cinaedi and Helicobacter fennelliae); Acinetobacter (e.g. A. baumanii, A. calcoaceticus, A. haemolyticus, A. johnsonii, A. junii, A. Iwoffi and A. radioresistens);
  • Pseudomonas (e.g. Ps. aeruginosa, Ps. maltophilia (Stenotrophomonas maltophilia), Ps. alcaligenes, Ps. chlororaphis, Ps. fluorescens, Ps. luteola. Ps. mendocina, Ps. monteilii, Ps. oryzihabitans, Ps. pertocinogena, Ps. pseudalcaligenes, Ps. putida and Ps. stutzeri);
  • Bacteriodes fragilis;
  • Peptococcus (e.g. Peptococcus niger);
  • Peptostreptococcus;
  • Clostridium (e.g. C. perfringens, C. difficile, C. botulinum, C. tetani, C. absonum, C. argentinense, C. baratii, C. bifermentans, C. beijerinckii, C. butyricum, C. cadaveris, C. carnis, C. celatum, C. clostridioforme, C. cochlearium, C. cocleatum, C. fallax, C. ghonii, C. glycolicum, C. haemolyticum, C. hastiforme, C. histolyticum, C. indolis, C. innocuum, C. irregulare, C. leptum, C. limosum, C. malenominatum, C. novyi, C. oroticum, C. paraputrificum, C. piliforme, C. putrefasciens, C. ramosum, C. septicum, C. sordelii, C. sphenoides, C. sporogenes, C. subterminale, C. symbiosum and C. tertium);
  • Mycoplasma (e.g. M. pneumoniae, M. hominis, M. genitalium and M. urealyticum);
  • Mycobacteria (e.g. Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium fortuitum, Mycobacterium marinum, Mycobacterium kansasii, Mycobacterium chelonae, Mycobacterium abscessus, Mycobacterium leprae, Mycobacterium smegmitis, Mycobacterium africanum, Mycobacterium alvei, Mycobacterium asiaticum, Mycobacterium aurum, Mycobacterium bohemicum, Mycobacterium bovis, Mycobacterium branderi, Mycobacterium brumae, Mycobacterium celatum, Mycobacterium chubense, Mycobacterium confluentis, Mycobacterium conspicuum, Mycobacterium cookii, Mycobacterium flavescens, Mycobacterium gadium, Mycobacterium gastri, Mycobacterium genavense, Mycobacterium gordonae, Mycobacterium goodii, Mycobacterium haemophilum, Mycobacterium hassicum, Mycobacterium intracellulare, Mycobacterium interjectum, Mycobacterium heidelberense, Mycobacterium lentiflavum, Mycobacterium malmoense, Mycobacterium microgenicum, Mycobacterium microti, Mycobacterium mucogenicum, Mycobacterium neoaurum, Mycobacterium nonchromogenicum, Mycobacterium peregrinum, Mycobacterium phlei, Mycobacterium scrofulaceum, Mycobacterium shimoidei, Mycobacterium simiae, Mycobacterium szulgai, Mycobacterium terrae, Mycobacterium thermoresistabile, Mycobacterium triplex, Mycobacterium triviale, Mycobacterium tusciae, Mycobacterium ulcerans, Mycobacterium vaccae, Mycobacterium wolinskyi and Mycobacterium xenopi);
  • Haemophilus (e.g. Haemophilus influenzae, Haemophilus ducreyi, Haemophilus aegyptius, Haemophilus parainfluenzae, Haemophilus haemolyticus and Haemophilus parahaemolyticus);
  • Actinobacillus (e.g. Actinobacillus actinomycetemcomitans, Actinobacillus equuli, Actinobacillus hominis, Actinobacillus lignieresii, Actinobacillus suis and Actinobacillus ureae);
  • Actinomyces (e.g. Actinomyces israelii);
  • Brucella (e.g. Brucella abortus, Brucella canis, Brucella melintensis and Brucella suis); Campylobacter (e.g. Campylobacter jejuni, Campylobacter coli, Campylobacter lari and Campylobacter fetus);
  • Listeria monocytogenes;
  • Vibrio (e.g. Vibrio cholerae and Vibrio parahaemolyticus, Vibrio alginolyticus, Vibrio carchariae, Vibrio fluvialis, Vibrio furnissii, Vibrio hollisae, Vibrio metschnikovii, Vibrio mimicus and Vibrio vulnificus);
  • Erysipelothrix rhusopathiae;
  • Corynebacteriaceae (e.g. Corynebacterium diphtheriae, Corynebacterium jeikeum and Corynebacterium urealyticum);
  • Spirochaetaceae, such as Borrelia (e.g. Borrelia recurrentis, Borrelia burgdorferi, Borrelia afzelii, Borrelia andersonii, Borrelia bissettii, Borrelia garinii, Borrelia japonica, Borrelia lusitaniae, Borrelia tanukii, Borrelia turdi, Borrelia valaisiana, Borrelia caucasica, Borrelia crocidurae, Borrelia duttoni, Borrelia graingeri, Borrelia hermsii, Borrelia hispanica, Borrelia latyschewii, Borrelia mazzottii, Borrelia parkeri, Borrelia persica, Borrelia turicatae and Borrelia venezuelensis) and Treponema (Treponema pallidum ssp. pallidum, Treponema pallidum ssp. endemicum, Treponema pallidum ssp. pertenue and Treponema carateum);
  • Pasteurella (e.g. Pasteurella aerogenes, Pasteurella bettyae, Pasteurella canis, Pasteurella dagmatis, Pasteurella gallinarum, Pasteurella haemolytica, Pasteurella multocida multocida, Pasteurella multocida gallicida, Pasteurella multocida septica, Pasteurella pneumotropica and Pasteurella stomatis);
  • Bordetella (e.g. Bordetella bronchiseptica, Bordetella hinzii, Bordetella holmseii, Bordetella parapertussis, Bordetella pertussis and Bordetella trematum);
  • Nocardiaceae, such as Nocardia (e.g. Nocardia asteroides and Nocardia brasiliensis); Rickettsia (e.g. Ricksettsii or Coxiella burnetii);
  • Legionella (e.g. Legionalla anisa, Legionalla birminghamensis, Legionalla bozemanii, Legionalla cincinnatiensis, Legionalla dumoffii, Legionalla feeleii, Legionalla gormanii, Legionalla hackeliae, Legionalla israelensis, Legionalla jordanis, Legionalla lansingensis, Legionalla longbeachae, Legionalla maceachernii, Legionalla micdadei, Legionalla oakridgensis, Legionalla pneumophila, Legionalla sainthelensi, Legionalla tucsonensis and Legionalla wadsworthii);
  • Moraxella catarrhalis;
  • Cyclospora cayetanensis;
  • Entamoeba histolytica;
  • Giardia lamblia;
  • Trichomonas vaginalis;
  • Toxoplasma gondii;
  • Stenotrophomonas maltophilia;
  • Burkholderia cepacia; Burkholderia mallei and Burkholderia pseudomallei;
  • Francisella tularensis;
  • Gardnerella (e.g. Gardneralla vaginalis and Gardneralla mobiluncus);
  • Streptobacillus moniliformis;
  • Flavobacteriaceae, such as Capnocytophaga (e.g. Capnocytophaga canimorsus, Capnocytophaga cynodegmi, Capnocytophaga gingivalis, Capnocytophaga granulosa, Capnocytophaga haemolytica, Capnocytophaga ochracea and Capnocytophaga sputigena);
  • Bartonella (Bartonella bacilliformis, Bartonella clarridgeiae, Bartonella elizabethae, Bartonella henselae, Bartonella quintana and Bartonella vinsonii arupensis);
  • Leptospira (e.g. Leptospira biflexa, Leptospira borgpetersenii, Leptospira inadai, Leptospira interrogans, Leptospira kirschneri, Leptospira noguchii, Leptospira santarosai and Leptospira weilii);
  • Spirillium (e.g. Spirillum minus);
  • Baceteroides (e.g. Bacteroides caccae, Bacteroides capillosus, Bacteroides coagulans, Bacteroides distasonis, Bacteroides eggerthii, Bacteroides forsythus, Bacteroides fragilis, Bacteroides merdae, Bacteroides ovatus, Bacteroides putredinis, Bacteroides pyogenes, Bacteroides splanchinicus, Bacteroides stercoris, Bacteroides tectus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides ureolyticus and Bacteroides vulgatus);
  • Prevotella (e.g. Prevotella bivia, Prevotella buccae, Prevotella corporis, Prevotella dentalis (Mitsuokella dentalis), Prevotella denticola, Prevotella disiens, Prevotella enoeca, Prevotella heparinolytica, Prevotella intermedia, Prevotella loeschii, Prevotella melaninogenica, Prevotella nigrescens, Prevotella oralis, Prevotella oris, Prevotella oulora, Prevotella tannerae, Prevotella venoralis and Prevotella zoogleoformans);
  • Porphyromonas (e.g. Porphyromonas asaccharolytica, Porphyromonas cangingivalis, Porphyromonas canoris, Porphyromonas cansulci, Porphyromonas catoniae, Porphyromonas circumdentaria, Porphyromonas crevioricanis, Porphyromonas endodontalis, Porphyromonas gingivalis, Porphyromonas gingivicanis, Porphyromonas levii and Porphyromonas macacae);
  • Fusobacterium (e.g. F. gonadiaformans, F. mortiferum, F. naviforme, F. necrogenes, F. necrophorum necrophorum, F. necrophorum fundiliforme, F. nucleatum nucleatum, F. nucleatum fusiforme, F. nucleatum polymorphum, F. nucleatum vincentii, F. periodonticum, F. russii, F. ulcerans and F. varium);
  • Chlamydia (e.g. Chlamydia trachomatis);
  • Cryptosporidium (e.g. C. parvum, C. hominis, C. canis, C. felis, C. meleagridis and C. muris);
  • Chlamydophila (e.g. Chlamydophila abortus (Chlamydia psittaci), Chlamydophila pneumoniae (Chlamydia pneumoniae) and Chlamydophila psittaci (Chlamydia psittaci));
  • Leuconostoc (e.g. Leuconostoc citreum, Leuconostoc cremoris, Leuconostoc dextranicum, Leuconostoc lactis, Leuconostoc mesenteroides and Leuconostoc pseudomesenteroides);
  • Gemella (e.g. Gemella bergeri, Gemella haemolysans, Gemella morbillorum and Gemella sanguinis); and
  • Ureaplasma (e.g. Ureaplasma parvum and Ureaplasma urealyticum).
Particular bacteria that may be treated using a combination of the invention include:
  • Staphylococci, such as Staph. aureus (either Methicillin-sensitive (i.e. MSSA) or Methicillin-resistant (i.e. MRSA)) and Staph. epidermidis;
  • Streptococci, such as Strept. agalactiae and Strept. pyogenes;
  • Bacillaceae, such as Bacillus anthracis;
  • Enterobacteriaceae, such as Escherichia coli, Klebsiella (e.g. Klebs. pneumoniae and Klebs. oxytoca) and Proteus (e.g. Pr. mirabilis, Pr. rettgeri and Pr. vulgaris);
  • Haemophilis influenzae;
  • Pseudomonas (e.g. Ps. aeruginosa, Ps. maltophilia (Stenotrophomonas maltophilia), Ps. alcaligenes, Ps. chlororaphis, Ps. fluorescens, Ps. luteola. Ps. mendocina, Ps. monteilii, Ps. oryzihabitans, Ps. pertocinogena, Ps. pseudalcaligenes, Ps. putida and Ps. stutzeri);
  • Enterococci, such as Enterococcus faecalis and Enterococcus faecium; and
  • Mycobacteria, such as Mycobacterium tuberculosis.
In an embodiment of the invention, the combination is for use in the prevention and/or treatment of a bacterial infection, wherein the bacterial infection is caused by Staph. aureus; for example, either MSSA or MRSA, or Pseudomonas aeruginosa.
In a preferred embodiment of the invention, there is provided the use of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable salt and/or solvate thereof, preferably the hydrochloride or mesylate salt thereof, in combination with tobramycin or a pharmaceutically acceptable salt and/or solvate thereof for the prevention and/or treatment of a bacterial infection caused by Pseudomonas aeruginosa; in particular for killing multiplying, non-multiplying and/or clinically latent microorganisms associated with such an infection.
In a further preferred embodiment of the invention, there is provided the use of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable salt and/or solvate thereof, preferably the hydrochloride or mesylate salt thereof, in combination with kanamycin, gentamicin or a pharmaceutically acceptable salt and/or solvate thereof for the prevention and/or treatment of a bacterial infection caused by Staphylococcus aureus, preferably MSSA or MRSA ; in particular for killing multiplying, non-multiplying and/or clinically latent microorganisms associated with such an infection.
The combination of the present invention may be used to prevent and/or to treat infections associated with any bacterial organisms, such as those mentioned above; in particular, it may be used for killing multiplying, non-multiplying and/or clinically latent microorganisms associated with such an infection.
Particular conditions which may be prevented and/or treated using the combination of the present invention include abscesses, bacterial conjunctivitis, bacterial keratitis, bone and joint infections, burn wounds, cellulitis, cholangitis, cholecystitis, cystic fibrosis, cystitis, diseases of the upper respiratory tract, eczema, empyema, endocarditis, epididymitis, erysipelas, eye infections, furuncles, gastrointestinal infections (gastroenteritis), genital infections, gingivitis, infected burns, infections following dental operations, infections in the oral region, infections associated with prostheses, intraabdominal abscesses, liver abscesses, mastitis, meningitis and infections of the nervous system, osteomyelitis, otitis, orchitis, pancreatitis, paronychia, pelveoperitonitis, peritonitis, peritonitis with appendicitis, pleural effusion, pneumonia, postoperative wound infections, postoperative gas gangrene, prostatitis, pulmonary emphysema, pyelonephritis, pyoderma, salpingitis, septic arthritis, septic infections, septicaemia, sinusitis, skin infections, systemic infections, toxic shock syndrome, or wound infections; or infections with MSSA or MRSA.
References herein to "treatment" extend to prophylaxis as well as the treatment of established diseases or symptoms.
It will be appreciated that one or more additional antimicrobial compounds may also be administered in combination with 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable salt and/or solvate thereof and the aminoglycoside antimicrobial agent in accordance with one aspect of the present invention.
Suitable additional antimicrobial compounds for use in the present invention include one or more compounds selected from the following:
  1. (1) β-Lactams, including:
    1. (i) penicillins, such as
      1. (I) benzylpenicillin, procaine benzylpenicillin, phenoxy-methylpenicillin, methicillin, propicillin, epicillin, cyclacillin, hetacillin, 6-aminopenicillanic acid, penicillic acid, penicillanic acid sulphone (sulbactam), penicillin G, penicillin V, phenethicillin, phenoxymethylpenicillinic acid, azlocillin, carbenicillin, cloxacillin, D-(-)-penicillamine, dicloxacillin, nafcillin and oxacillin,
      2. (II) penicillinase-resistant penicillins (e.g. flucloxacillin),
      3. (III) broad-spectrum penicillins (e.g. ampicillin, amoxicillin, metampicillin and bacampicillin),
      4. (IV) antipseudomonal penicillins (e.g. carboxypenicillins such as ticarcillin or ureidopenicillins such as piperacillin),
      5. (V) mecillinams (e.g. pivmecillinam), or
      6. (VI) combinations of any two or more of the agents mentioned at (I) to (V) above, or combinations of any of the agents mentioned at (I) to (V) above with a β-lactamase inhibitor such as tazobactam or, particularly, clavulanic acid (which acid is optionally in metal salt form, e.g. in salt form with an alkali metal such as sodium or, particularly, potassium);
    2. (ii) cephalosporins, such as cefaclor, cefadroxil, cefalexin (cephalexin), cefcapene, cefcapene pivoxil, cefdinir, cefditoren, cefditoren pivoxil, cefixime, cefotaxime, cefpirome, cefpodoxime, cefpodoxime proxetil, cefprozil, cefradine, ceftazidime, cefteram, cefteram pivoxil, ceftriaxone, cefuroxime, cefuroxime axetil, cephaloridine, cephacetrile, cephamandole, cephaloglycine, ceftobiprole, PPI-0903 (TAK-599), 7-aminocephalosporanic acid, 7-aminodes-acetoxycephalosporanic acid, cefamandole, cefazolin, cefmetazole, cefoperazone, cefsulodin, cephalosporin C zinc salt, cephalothin, cephapirin; and
    3. (iii) other β-lactams, such as monobactams (e.g. aztreonam), carbapenems (e.g. imipenem (optionally in combination with a renal enzyme inhibitor such as cilastatin), meropenem, ertapenem, doripenem (S-4661) and RO4908463 (CS-023)), penems (e.g. faropenem) and 1-oxa-β-lactams (e.g. moxalactam).
  2. (2) Tetracyclines, such as tetracycline, demeclocycline, doxycycline, lymecycline, minocycline, oxytetracycline, chlortetracycline, meclocycline and methacycline, as well as glycylcyclines (e.g. tigecycline).
  3. (3) One or more additional aminoglycosides, such as amikacin, gentamicin, netilmicin, neomycin, streptomycin, tobramycin, amastatin, butirosin, butirosin A, daunorubicin, dibekacin, dihydrostreptomycin, G 418, hygromycin B, kanamycin B, kanamycin, kirromycin, paromomycin, ribostamycin, sisomicin, spectinomycin, streptozocin and thiostrepton.
  4. (4)
    1. (i) Macrolides, such as azithromycin, clarithromycin, erythromycin, roxithromycin, spiramycin, amphotericins B (e.g. amphotericin B), bafilomycins (e.g. bafilomycin A1), brefeldins (e.g. brefeldin A), concanamycins (e.g. concanamycin A), filipin complex, josamycin, mepartricin, midecamycin, nonactin, nystatin, oleandomycin, oligomycins (e.g. oligomycin A, oligomycin B and oligomycin C), pimaricin, rifampicin, rifamycin, rosamicin, tylosin, virginiamycin and fosfomycin.
    2. (ii) Ketolides such as telithromycin and cethromycin (ABT-773).
    3. (iii) Lincosamines, such as lincomycin.
  5. (5) Clindamycin and clindamycin 2-phosphate.
  6. (6) Phenicols, such as chloramphenicol and thiamphenicol.
  7. (7) Steroids, such as fusidic acid (optionally in metal salt form, e.g. in salt form with an alkali metal such as sodium).
  8. (8) Glycopeptides such as vancomycin, teicoplanin, bleomycin, phleomycin, ristomycin, telavancin, dalbavancin and oritavancin.
  9. (9) Oxazolidinones, such as linezolid and AZD2563.
  10. (10) Streptogramins, such as quinupristin and dalfopristin, or a combination thereof.
  11. (11)
    1. (i) Peptides, such as polymyxins (e.g. colistin and polymyxin B), lysostaphin, duramycin, actinomycins (e.g. actinomycin C and actinomycin D), actinonin, 7-aminoactinomycin D, antimycin A, antipain, bacitracin, cyclosporin A, echinomycin, gramicidins (e.g. gramicidin A and gramicidin C), myxothiazol, nisin, paracelsin, valinomycin and viomycin.
    2. (ii) Lipopeptides, such as daptomycin.
    3. (iii) Lipoglycopeptides, such as ramoplanin.
  12. (12) Sulfonamides, such as sulfamethoxazole, sulfadiazine, sulfaquinoxaline, sulfathiazole (which latter two agents are optionally in metal salt form, e.g. in salt form with an alkali metal such as sodium), succinylsulfathiazole, sulfadimethoxine, sulfaguanidine, sulfamethazine, sulfamonomethoxine, sulfanilamide and sulfasalazine.
  13. (13) Trimethoprim, optionally in combination with a sulfonamide, such as sulfamethoxazole (e.g. the combination co-trimoxazole).
  14. (14) Antituberculous drugs, such as isoniazid, rifampicin, rifabutin, pyrazinamide, ethambutol, streptomycin, amikacin, capreomycin, kanamycin, quinolones, para-aminosalicylic acid, cycloserine and ethionamide.
  15. (15) Antileprotic drugs, such as dapsone, rifampicin and clofazimine.
  16. (16)
    1. (i) Nitroimidazoles, such as metronidazole and tinidazole.
    2. (ii) Nitrofurans, such as nitrofurantoin.
  17. (17) Quinolones, such as nalidixic acid, norfloxacin, ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, gatifloxacin, gemifloxacin, garenoxacin, DX-619, WCK 771 (the arginine salt of S-(-)-nadifloxacin), 8-quinolinol, cinoxacin, enrofloxacin, flumequine, lomefloxacin, oxolinic acid and pipemidic acid.
  18. (18) Amino acid derivatives, such as azaserine, bestatin, D-cycloserine, 1,10-phenanthroline, 6-diazo-5-oxo-L-norleucine and L-alanyl-L-1-aminoethyl-phosphonic acid.
  19. (19) Aureolic acids, such as chromomycin A3, mithramycin A and mitomycin C.
  20. (20) Benzochinoides, such as herbimycin A.
  21. (21) Coumarin-glycosides, such as novobiocin.
  22. (22) Diphenyl ether derivatives, such as irgasan.
  23. (23) Epipolythiodixopiperazines, such as gliotoxin from Gliocladium fimbriatum.
  24. (24) Fatty acid derivatives, such as cerulenin.
  25. (25) Glucosamines, such as 1-deoxymannojirimycin, 1-deoxynojirimycin and N-methyl-1-deoxynojirimycin.
  26. (26) Indole derivatives, such as staurosporine.
  27. (27) Diaminopyrimidines, such as iclaprim (AR-100).
  28. (28) Macrolactams, such as ascomycin.
  29. (29) Taxoids, such as paclitaxel.
  30. (30) Statins, such as mevastatin.
  31. (31) Polyphenolic acids, such as (+)-usnic acid.
  32. (32) Polyethers, such as lasalocid A, lonomycin A, monensin, nigericin and salinomycin.
  33. (33) Picolinic acid derivatives, such as fusaric acid.
  34. (34) Peptidyl nucleosides, such as blasticidine S, nikkomycin, nourseothricin and puromycin.
  35. (35) Nucleosides, such as adenine 9-β-D-arabinofuranoside, 5-azacytidine, cordycepin, formycin A, tubercidin and tunicamycin.
  36. (36) Pleuromutilins, such as GSK-565154, GSK-275833 and tiamulin.
  37. (37) Peptide deformylase inhibitors, such as LBM415 (NVP PDF-713) and BB 83698.
  38. (38) Antibacterial agents for the skin, such as fucidin, benzamycin, clindamycin, erythromycin, tetracycline, silver sulfadiazine, chlortetracycline, metronidazole, framycitin, gramicidin, neomycin sulfate, polymyxins (e.g. polymixin B) and gentamycin.
  39. (39) Miscellaneous agents, such as methenamine (hexamine), doxorubicin, piericidin A, stigmatellin, actidione, anisomycin, apramycin, coumermycin A1, L(+)-lactic acid, cytochalasins (e.g. cytochalasin B and cytochalasin D), emetine and ionomycin.
  40. (40) Antiseptic agents, such as chlorhexidine, phenol derivatives (e.g. thymol and triclosan), quarternary ammonium compounds (e.g. benzalkonium chloride, cetylpyridinium chloride, benzethonium chloride, cetrimonium bromide, cetrimonium chloride and cetrimonium stearate), octenidine dihydrochloride, and terpenes (e.g. terpinen-4-ol).
As used herein the term "pharmaceutically acceptable derivative" means:
  1. (a) pharmaceutically acceptable salts; and/or
  2. (b) solvates (including hydrates).
Suitable acid addition salts include carboxylate salts (e.g. formate, acetate, trifluoroacetate, propionate, isobutyrate, heptanoate, decanoate, caprate, caprylate, stearate, acrylate, caproate, propiolate, ascorbate, citrate, glucuronate, glutamate, glycolate, α-hydroxybutyrate, lactate, tartrate, phenylacetate, mandelate, phenylpropionate, phenylbutyrate, benzoate, chlorobenzoate, methylbenzoate, hydroxybenzoate, methoxybenzoate, dinitrobenzoate, o-acetoxybenzoate, salicylate, nicotinate, isonicotinate, cinnamate, oxalate, malonate, succinate, suberate, sebacate, fumarate, malate, maleate, hydroxymaleate, hippurate, phthalate or terephthalate salts), halide salts (e.g. chloride, bromide or iodide salts), sulfonate salts (e.g. benzenesulfonate, methyl-, bromo- or chloro-benzenesulfonate, xylenesulfonate, methanesulfonate, ethanesulfonate, propanesulfonate, hydroxyethanesulfonate, 1- or 2-naphthalene-sulfonate or 1,5-naphthalenedisulfonate salts) or sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate or nitrate salts.
A preferred salt form of gentamicin is the sodium salt thereof, gentamicin sodium.
A preferred salt form of kanamycin is the sulphate salt thereof, kanamycin sulphate.
A preferred salt form of tobramycin is the sulphate salt thereof, tobramycin sulphate.
A preferred salt form of neomycin is the sulphate salt thereof, neomycin sulphate.
For the avoidance of doubt, references herein to 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline mean a compound having the following chemical structure:
4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof may be prepared by methods known in the art, for example by following the methods disclosed in International Patent Application, Publication Numbers WO2007054693 and WO2008056151 . Preferred pharmaceutically acceptable derivatives of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline include acid addition salts thereof, particularly the hydrochloride and mesylate salts thereof.
Aminoglycoside antimicrobial agents may be prepared according to known methods and/or are available commercially. For example, tobramycin, kanamycin and gentamicin are commercially available from Sigma Aldrich Ltd.
The compounds included in the combination of the invention may be administered simultaneously or sequentially and, when administered sequentially, 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable salt and/or solvate thereof or the aminoglycoside antimicrobial agent as defined herein, may be administered first. When administration is simultaneous, the combination may be administered either in the same or a different pharmaceutical composition.
The compounds included in the combination of the invention may be administered as the raw material but the active ingredients are preferably provided in the form of pharmaceutical compositions.
The active ingredients may be used either as separate formulations or as a single combined formulation. When combined in the same formulation it will be appreciated that the two compounds must be stable and compatible with each other and the other components of the formulation.
Formulations of the invention include those suitable for oral, parenteral (including subcutaneous e.g. by injection or by depot tablet, intradermal, intrathecal, intramuscular e.g. by depot and intravenous), rectal and topical (including dermal, buccal and sublingual) or in a form suitable for administration by inhalation or insufflation administration. The most suitable route of administration may depend upon the condition and disorder of the patient.
Preferably, the compositions of the invention are formulated for oral or topical administration or for administration by inhalation.
The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy e.g. as described in " Remington: The Science and Practice of Pharmacy", Lippincott Williams and Wilkins, 21st Edition, (2005). Suitable methods include the step of bringing into association to active ingredients with a carrier which constitutes one or more excipients. In general, formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation. It will be appreciated that when the two active ingredients are administered independently, each may be administered by a different means.
When formulated with excipients, the active ingredients may be present in a concentration from 0.1 to 99.5% (such as from 0.5 to 95%) by weight of the total mixture; conveniently from 30 to 95% for tablets and capsules and 0.01 to 50% for liquid preparations.
A suitable concentration for 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable salt and/or solvate thereof is from about 0.1 to about 10%, preferably from about 0.1 to about 5%, for example 0.1, 0.25, 0.5, 1, 2, 3, 4 or 5% by weight of the total mixture.
A suitable concentration for an aminoglycoside antimicrobial agent or a pharmaceutically acceptable salt and/or solvate thereof is from 0.01 to 10%, for example 0.01, 0.05, 0.1, 0.25, 0.3, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10% by weight of the total mixture.
Formulations suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets (e.g. chewable tablets in particular for paediatric administration), each containing a predetermined amount of active ingredient; as powder or granules; as a solution or suspension in an aqueous liquid or non-aqueous liquid; or as an oil-in-water liquid emulsion or water-in-oil liquid emulsion. The active ingredients may also be presented a bolus, electuary or paste.
A tablet may be made by compression or moulding, optionally with one or more excipients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with other conventional excipients such as binding agents (e.g. syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch, polyvinylpyrrolidone and/or hydroxymethyl cellulose), fillers (e.g. lactose, sugar, microcrystalline cellulose, maize-starch, calcium phosphate and/or sorbitol), lubricants (e.g. magnesium stearate, stearic acid, talc, polyethylene glycol and/or silica), disintegrants (e.g. potato starch, croscarmellose sodium and/or sodium starch glycolate) and wetting agents (e.g. sodium lauryl sulphate). Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered active ingredient with an inert liquid diluent. The tablets may be optionally coated or scored and may be formulated so as to provide controlled release (e.g. delayed, sustained, or pulsed release, or a combination of immediate release and controlled release) of the active ingredients.
Alternatively, the active ingredients may be incorporated into oral liquid preparations such as aqueous or oily suspensions, solutions, emulsions, syrups or elixirs. Formulations containing the active ingredients may also be presented as a dry product for constitution with water or another suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents (e.g. sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxymethyl cellulose, carboxymethyl cellulose, aluminium stearate gel and/or hydrogenated edible fats), emulsifying agents (e.g. lecithin, sorbitan mono-oleate and/or acacia), non-aqueous vehicles (e.g. edible oils, such as almond oil, fractionated coconut oil, oily esters, propylene glycol and/or ethyl alcohol), and preservatives (e.g. methyl or propyl p-hydroxybenzoates and/or sorbic acid).
Topical compositions, which are useful for treating disorders of the skin or of membranes accessible by digitation (such as membrane of the mouth, vagina, cervix, anus and rectum), include creams, ointments, lotions, sprays, gels and sterile aqueous solutions or suspensions. As such, topical compositions include those in which the active ingredients are dissolved or dispersed in a dermatological vehicle known in the art (e.g. aqueous or non-aqueous gels, ointments, water-in-oil or oil-in-water emulsions). Constituents of such vehicles may comprise water, aqueous buffer solutions, non-aqueous solvents (such as ethanol, isopropanol, benzyl alcohol, 2-(2-ethoxyethoxy)ethanol, propylene glycol, propylene glycol monolaurate, glycofurol or glycerol), oils (e.g. a mineral oil such as a liquid paraffin, natural or synthetic triglycerides such as Miglyol™, or silicone oils such as dimethicone). Depending, inter alia, upon the nature of the formulation as well as its intended use and site of application, the dermatological vehicle employed may contain one or more components selected from the following list: a solubilising agent or solvent (e.g. a β-cydodextrin, such as hydroxypropyl β-cyclodextrin, or an alcohol or polyol such as ethanol, propylene glycol or glycerol); a thickening agent (e.g. hydroxymethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose or carbomer); a gelling agent (e.g. a polyoxyethylene-polyoxypropylene copolymer); a preservative (e.g. benzyl alcohol, benzalkonium chloride, chlorhexidine, chlorbutol, a benzoate, potassium sorbate or EDTA or salt thereof); and pH buffering agent(s) (e.g. a mixture of dihydrogen phosphate and hydrogen phosphate salts, or a mixture of citric acid and a hydrogen phosphate salt). Topical formulations may also be formulated as a transdermal patch.
Methods of producing topical pharmaceutical compositions such as creams, ointments, lotions, sprays and sterile aqueous solutions or suspensions are well known in the art. Suitable methods of preparing topical pharmaceutical compositions are described, e.g. in WO9510999 , US 6974585 , WO2006048747 , as well as in documents cited in any of these references.
Topical pharmaceutical compositions according to the present invention may be used to treat a variety of skin or membrane disorders, such as infections of the skin or membranes (e.g. infections of nasal membranes, axilla, groin, perineum, rectum, dermatitic skin, skin ulcers, and sites of insertion of medical equipment such as i.v. needles, catheters and tracheostomy or feeding tubes) with any of the bacteria, fungi described above, (e.g. any of the Staphylococci, Streptococci, Mycobacteria or Pseudomonas organisms mentioned hereinbefore, such as S. aureus (e.g. Methicillin resistant S. aureus (MRSA))).
Topical compositions of the invention may be used for pre-operative surgical hand disinfection, antiseptic handwashing, and pre- and post-operative antisepsis for patients undergoing elective surgery.
Particular bacterial conditions that may be treated by topical pharmaceutical compositions of the present invention also include the skin- and membrane-related conditions disclosed hereinbefore.
In a preferred embodiment of the invention, there is provided a topical pharmaceutical composition for the nasal decolonisation of MRSA.
Compositions for use according to the invention may be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredients. The pack may, e.g. comprise metal or plastic foil, such as a blister pack. Where the compositions are intended for administration as two separate compositions these may be presented in the form of a twin pack.
Pharmaceutical compositions may also be prescribed to the patient in "patient packs" containing the whole course of treatment in a single package, usually a blister pack. Patient packs have an advantage over traditional prescriptions, where a pharmacist divides a patients' supply of a pharmaceutical from a bulk supply, in that the patient always has access to the package insert contained in the patient pack, normally missing in traditional prescriptions. The inclusion of the package insert has been shown to improve patient compliance with the physician's instructions.
The administration of the combination of the invention by means of a single patient pack, or patients packs of each composition, including a package insert directing the patient to the correct use of the invention is a further feature of this invention.
Described herein is therefore a patient pack comprising at least one active ingredient of the combination according to the invention, i.e. at least one of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof and an aminoglycoside antimicrobial agent, and an information insert containing directions on the use of the combination of the invention.
Also described is a double pack comprising in association for separate administration, 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof and an aminoglycoside antimicrobial agent.
The amount of active ingredients required for use in treatment will vary with the nature of the condition being treated and the age and condition of the patient, and will ultimately be at the discretion of the attendant physician or veterinarian. In general however, doses employed for adult human treatment will typically be in the range of 0.02 to 5000 mg per day, preferably 1 to 1500 mg per day. The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, e.g. as two, three, four or more sub-does per day.
Biological Tests
Test procedures that may be employed to determine the biological (e.g. bactericidal or antimicrobial) activity of the active ingredients include those known to persons skilled in the art for determining:
  1. (a) bactericidal activity against clinically latent bacteria; and
  2. (b) antimicrobial activity against log phase bacteria.
In relation to (a) above, methods for determining activity against clinically latent bacteria include a determination, under conditions known to those skilled in the art (such as those described in Nature Reviews, Drug Discovery 1, 895-910 (2002)), of Minimum Stationarycidal Concentration ("MSC") or Minimum Dormicidal Concentration ("MDC") for a test compound.
By way of example, WO2000028074 describes a suitable method of screening compounds to determine their ability to kill clinically latent microorganisms. A typical method may include the following steps:
  1. (1) growing a bacterial culture to stationary phase;
  2. (2) treating the stationary phase culture with one or more antimicrobial agents at a concentration and or time sufficient to kill growing bacteria, thereby selecting a phenotypically resistant sub-population;
  3. (3) incubating a sample of the phenotypically resistant subpopulation with one or more test compounds or agents; and
  4. (4) assessing any antimicrobial effects against the phenotypically resistant subpopulation.
According to this method, the phenotypically resistant sub-population may be seen as representative of clinically latent bacteria which remain metabolically active in vivo and which can result in relapse or onset of disease.
In relation to (b) above, methods for determining activity against log phase bacteria include a determination, under standard conditions (i.e. conditions known to those skilled in the art, such as those described in WO2005014585 ), of Minimum Inhibitory Concentration (MIC) or Minimum Bactericidal Concentration (MBC) for a test compound. Specific examples of such methods are described below.
Examples Example 1: In vitro activity of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline in combination with kanamycin or gentamicin against log phase S. aureus Materials and Methods Bacterial strains and culture medium
Staphylococcus aureus (Oxford); Gram positive; Reference strain.
Nutrient Broth No. 2 (NB) (Oxoid, Cambridge, UK) was used for overnight growth of bacteria. Iso-Sensitest Broth (Oxoid) was used for evaluation of Minimum inhibitory concentrations (MICs), susceptibility tests for antimicrobials, and efficacy of antimicrobial combinations.
Trypton soya agar (TSA) (Oxoid, Cambridge, UK) was used for growth and quantification of organisms. All media were autoclaved at 121°C for 15 minutes prior to use.
Bacterial growth conditions
Bacterial cultures were prepared by inoculation of 10 ml of NB with a single colony of bacteria on blood agar or TSA and incubated at 37°C with continuous shaking at 100 rpm for 16 to 24 hours. The overnight cultures were used for experimental tests.
For CFU counting, the bacterial suspensions were diluted using sterile deionized water or phosphate-buffered saline (PBS, Sigma Aldrich Ltd, Poole, Dorset, UK). 100 µl of 10-fold serial dilutions of bacteria culture were plated on one third of TSA plates in triplicate and incubated 24 to 48 hours at 37°C. The number of cells presented on the plates was counted using an AcoLyte colony counter (Synbiosis) and results were expressed as Colony Forming Units/ml (CFU/ml).
Antibiotics
Kanamycin and gentamicin were purchased from Sigma Aldrich Ltd.
4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline (in hydrochloride salt form) was provided by Helperby Therapeutics.
Stocks of 10 mg/ml of kanamycin, gentamicin and 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline were prepared by dilution in dimethyl sulfoxide (DMSO) or water respectively. The antibiotic solutions were stored at -20°C.
Evaluation of MIC and MBC
Minimum inhibitory concentration (MIC) analyses for kanamycin, gentamicin and 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline were performed in Iso-Sensitest broth using a broth dilution method and were determined as the lowest concentration of antimicrobial agent that inhibited visible growth after overnight incubation at 37°C. The stock solution of each drug was diluted to required concentrations. 10 µl of drug from each dilution was taken and mixed with 290 µl of culture with 106 of bacterial cells on a 96-well plate to make the final required concentrations (µg/ml).
The plates were read at 405 nm using a 96-well plate reader Elx 800 equipped with a 405-nm filter (Bio-Tek) before and after incubation. The MIC values of the drugs were determined by comparison of the optical density reading between prior and post drug treatment.
Minimum bactericidal concentration (MBC) was determined by subculturing 100µl of dilutions from the 96-well plate on fresh drug-free TSA agar plates and incubating further for 24 to 48 hours at 37°C. The highest dilution that showed no single bacterial colony on TSA plates was taken as the MBC.
Efficacy of antimicrobial combinations
The antimicrobial activity of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline in combination with (a) kanamycin and (b) gentamicin against S. aureus, in a concentration range from below to above the MIC, was assessed in a suspension assay by the time-kill curve method.
Serial double dilutions of the antimicrobial compounds were prepared as follows: 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline from 16 µg/ml to 0.25µg/ml; kanamycin from 4 to 0.24 µg/ml; and gentamicin from 8 to 0.5 µg/ml. Ten microlitres of each antimicrobial solution were added to the rows of a 96-well microtitre plate in diminishing concentrations, and then 10µl of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline was added to the columns in decreasing concentrations. The wells were then inoculated with 280µl of S. aureus (Oxford strain) suspension containing 107 CFU/ml of inocula. Drug free controls were also included.
The microtitre plates were incubated at 37°C for 16 to 24 hours, read in a 96-well plate reader, then samples were diluted and 100 µl of each dilution was plated out on TSA plates. After 24 to 48 hours incubation CFU was counted. Each test was performed in triplicate and repeated twice. Synergy was defined as a 2 log10 decrease in colony counts, when antibacterial activity of combinations was compared with that of the most active single agent.
Statistical analysis
The mean bacterial colony count at varying time points was compared by the two-tailed t-test with unequal variance. P values of ≤0.05 indicated significant difference.
Results
Kanamycin 8 -
Gentamicin 1 8
4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline 8 16
Time-kill studies for 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline in combination with (a) kanamycin and (b) gentamicin
The kill curve results for combinations of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline (4 µg/ml) with kanamycin and gentamicin against S. aureus are shown in Figures 1 and 2. Results are displayed as means of log reduction in viable organisms ± standard deviation (*P<0.005, **P<0.001 and ***P<0.0001).
The growth control for these experiments is not shown but was grossly turbid during the time of experiments.
Conclusions
Significant synergistic activities were observed for kanamycin (2, 4 and 8 µg/ml) in combination with 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline (4 µg/ml).
Similar synergies were observed for gentamicin (8, 4, 2 and 1 µg/ml) in combination with 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline (4 µg/ml).
Example 2: In vitro activity of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline in combination with tobramycin against stationary phase Pseudomonas aeruginosa Materials and Methods Bacterial strains and culture medium Pseudomonas aeruginosa (clinical isolate). Bacterial growth conditions
A single colony of Ps. aeruginosa was inoculated in 10 ml of Nutrient Broth No. 2 (NB) (Oxoid) which was incubated overnight at 37°C with continuous shaking at 120 rpm. 200 µl of the overnight culture was added into a 500 ml screw-cap which contained 100 ml of NB. The 100 ml culture was incubated at 37°C with continuous shaking for 5 to 6 days. The cultures were diluted with phosphate buffered saline to 107 CFU/ml.
Antibiotics
Tobramycin was purchased from Sigma Aldrich Ltd.
4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline (in mesylate salt form) was provided by Helperby Therapeutics.
Stocks of 10 mg/ml of tobramycin and 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline mesylate were prepared by dilution in water. The antibiotic solutions were stored at -20°C.
The bacterial cell suspension was incubated with tobramycin and 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline mesylate at different concentrations. The activities of the combination and each of the individual drugs were measured by CFU counts at 0, 2, 4, 6 and 8 hours. CFU counts were performed as follows: from serial 10-fold dilutions of the experimental cultures, 100 µl samples were added to triplicate plates of nutrient agar plates (Oxoid). Colony forming units (CFU) were counted after incubation of the plates at 37°C for 24 hours.
Results
The kill curve results for combinations of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline mesylate (HT61) (32, 16 or 8 µg/ml) with tobramycin (T) (2 or 1 µg/ml) against Pseudomonas aeruginosa are shown in Figures 3 to 7. Results are displayed as means of log reduction in viable organisms ± standard deviation (*P<0.005, **P<0.001 and ***P<0.0001).
Conclusions
4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline mesylate alone at 32, 16 and 8 µg/ml showed slight or no activities against stationary phase P. aeruginosa. In addition, tobramycin alone at 2 and 1 µg/ml had very low or no activities. However, tobramycin in combination with 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline mesylate killed the bacteria rapidly. The CFU counts reached 0 at 4 or 6 hours after incubation. These data are indicative of synergistic activity.
Example 3: In vitro activity of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline in combination with tobramycin against log phase Pseudomonas aeruginosa by chequerboard analysis Materials and Methods Bacterial strains and culture medium Pseudomonas aeruginosa (clinical isolate).
Nutrient Broth No. 2 (NB) (Oxoid, Cambridge, UK) was used for overnight growth of bacteria.
Iso-Sensitest Broth (Oxoid) was used for evaluation of Minimum inhibitory concentrations (MICs).
Bacterial growth conditions
P. aeruginosa was grown in 10 ml of NB overnight at 37°C with continuous shaking at 120 rpm. The overnight cultures were diluted 1000 X with iso-sensitest broth to obtain a cell suspension containing the bacteria at 106 CFU/ml. The cultures were incubated at 37ºC with shaking for 1-2 hours served as log-phase cultures. Viability of the bacteria was estimated by colony forming unit (CFU) counts.
Antibiotics
Tobramycin was purchased from Sigma Aldrich Ltd.
4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline (in mesylate salt form) was provided by Helperby Therapeutics.
Drug assay of log phase bacteria
The combinations of tobramycin and 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline mesylate were prepared using 96 well plates using the drug concentrations starting from 16 ug/ml for tobramycin and 64 ug/ml for HT61. The two drugs were serially diluted twofold to 0 and combined in a pattern of an array.
Compound preparation
Stocks of 10 mg/ml of tobramycin and 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline mesylate were prepared by dilution in water. The antibiotic solutions were stored at -20°C.
Determination of activities
The optical density of the bacterial cells was read at 405 nm using a plate reader (Bio TEK). The MIC concentration was determined as the lowest concentration of drug which inhibits the bacterial growth. The MIC values of the drugs were determined by comparison of the optical density reading between prior and post drug treatment.
Results
Tobramycin HT61
µg/ml 16 8 4 2 1 0.5 0.25 0.125 0.0625 0.03125 0.01563 0
64 0.53 0.85 0.85 0.82 1.02 0.84 2.73 2.85 2.88 2.92 2.99 3.01
32 0.42 0.52 0.52 0.51 0.52 0.61 3.00 3.04 3.13 3.13 3.13 3.09
16 0.27 0.45 0.44 0.44 0.45 1.45 3.04 3.15 3.08 3.10 3.23 3.11
8 0.24 0.44 0.43 0.43 0.44 2.24 3.06 3.10 3.13 3.14 3.16 3.15
4 0.24 0.44 0.44 0.43 1.12 2.19 2.98 3.09 3.09 3.12 3.13 3.11
2 0.24 0.43 0.44 0.44 0.44 2.00 3.07 3.18 3.14 3.11 3.23 3.12
1 0.24 0.44 0.43 0.44 0.44 1.97 3.07 3.11 3.15 3.16 3.17 3.16
0 0.23 0.44 0.47 0.44 0.46 2.19 3.04 3.15 3.16 3.24 3.25 3.25
Tobramycin HT61
16 8 4 2 1 0.5 0.25 0.125 0.0625 0.03125 0.01563 0
64 0.83 0.78 0.79 0.81 0.81 0.83 2.71 2.86 2.89 2.91 2.94 3.09
32 0.54 0.50 0.52 0.53 0.53 0.65 2.95 2.99 3.05 3.11 3.10 3.04
16 0.48 0.44 0.44 0.44 0.45 0.83 3.01 3.18 3.05 3.06 3.24 3.07
8 0.43 0.44 0.43 0.44 0.43 2.26 3.06 3.06 3.07 3.11 3.14 3.10
4 0.49 0.44 0.46 0.44 0.45 2.40 3.01 3.06 3.07 3.10 3.15 3.10
2 0.44 0.44 0.44 0.44 0.44 1.97 2.95 3.07 3.09 3.16 3.14 3.11
1 0.43 0.44 0.44 0.43 0.44 1.98 3.01 3.02 3.08 3.12 3.13 3.08
0 0.48 0.44 0.50 0.45 0.46 2.18 2.97 3.08 3.09 3.18 3.14 3.28
4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline mesylate alone has no MIC against P. aeruginosa. Tobramycin MIC was 1 µg/ml. However, with tobramycin at 0.5 µg/ml, HT61 MIC was observed at 16 µg/ml.
Conclusions
There was no MIC shown for 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline mesylate within the concentration range used. Tobramycin MIC was 1 µg/ml. However, in combination with tobramycin 0.5 µg/ml, an MIC of 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline mesylate was observed at 16 µg/ml. There was a combined activity seen when 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline mesylate was used in combination with tobramycin.

Claims (11)

  1. A combination comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable salt and/or solvate thereof and an aminoglycoside antimicrobial agent or a pharmaceutically acceptable salt and/or solvate thereof, wherein the aminoglycoside antimicrobial agent is selected from the group consisting of arbekacin, amikacin, apramycin, gentamicin, netilmicin, neomycin, streptomycin, tobramycin, amastatin, butirosin, butirosin A, daunorubicin, dibekacin, dihydrostreptomycin, G 418, hygromycin B, kanamycin B, kanamycin, kirromycin, paromomycin, rhodostreptomycin, ribostamycin, sisomicin, spectinomycin, streptozocin and thiostrepton, or a pharmaceutically acceptable salt and/or solvate thereof.
  2. A combination according to claim 1 for use in the prevention and/or treatment of a bacterial infection, wherein the bacterial infection is caused by Staphylococcus aureus or Pseudomonas aeruginosa.
  3. A combination according to claim 1 or a combination for use according to claim 2, comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline hydrochloride.
  4. A combination according to claim 1 or a combination for use according to claim 2 comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline mesylate.
  5. A combination according to any preceding claim wherein the aminoglycoside antimicrobial agent is neomycin, kanamycin, gentamicin or tobramycin, or a pharmaceutically acceptable salt and/or solvate thereof.
  6. A combination for use according to claim 2, wherein said use comprises killing multiplying and/or clinically latent bacteria associated with such an infection.
  7. A combination for use according to claim 2 wherein the combination is for use in the prevention and/or treatment of abscesses, bacterial conjunctivitis, bacterial keratitis, bone and joint infections, burn wounds, cellulitis, cholangitis, cholecystitis, cystic fibrosis, cystitis, diseases of the upper respiratory tract, eczema, empyema, endocarditis, epididymitis, erysipelas, eye infections, furuncles, gastrointestinal infections (gastroenteritis), genital infections, gingivitis, infected burns, infections following dental operations, infections in the oral region, infections associated with prostheses, intraabdominal abscesses, liver abscesses, mastitis, meningitis and infections of the nervous system, osteomyelitis, otitis, orchitis, pancreatitis, paronychia, pelveoperitonitis, peritonitis, peritonitis with appendicitis, pleural effusion, pneumonia, postoperative wound infections, postoperative gas gangrene, prostatitis, pulmonary emphysema, pyelonephritis, pyoderma, salpingitis, septic arthritis, septic infections, septicaemia, sinusitis, skin infections, systemic infections, toxic shock syndrome, or wound infections; or infections with MSSA or MRSA.
  8. A pharmaceutical composition comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable salt and/or solvate thereof, an aminoglycoside antimicrobial agent or a pharmaceutically acceptable salt and/or solvate thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier, wherein the aminoglycoside antimicrobial agent is selected from the group consisting of arbekacin, amikacin, apramycin, gentamicin, netilmicin, neomycin, streptomycin, tobramycin, amastatin, butirosin, butirosin A, daunorubicin, dibekacin, dihydrostreptomycin, G 418, hygromycin B, kanamycin B, kanamycin, kirromycin, paromomycin, rhodostreptomycin, ribostamycin, sisomicin, spectinomycin, streptozocin and thiostrepton, or a pharmaceutically acceptable salt and/or solvate thereof.
  9. A pharmaceutical composition according to claim 8 which is formulated for oral or topical administration.
  10. A pharmaceutical composition according to claim 8 which is formulated for administration by inhalation.
  11. A product comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable salt and/or solvate thereof and an aminoglycoside antimicrobial agent or a pharmaceutically acceptable salt and/or solvate thereof as a combined preparation for simultaneous, separate or sequential use in the prevention and/or treatment of a bacterial infection, wherein the infection is caused by Staphylococcus aureus or Pseudomonas aeruginosa; and wherein the aminoglycoside antimicrobial agent is selected from the group consisting of arbekacin, amikacin, apramycin, gentamicin, netilmicin, neomycin, streptomycin, tobramycin, amastatin, butirosin, butirosin A, daunorubicin, dibekacin, dihydrostreptomycin, G 418, hygromycin B, kanamycin B, kanamycin, kirromycin, paromomycin, rhodostreptomycin, ribostamycin, sisomicin, spectinomycin, streptozocin and thiostrepton, or a pharmaceutically acceptable salt and/or solvate thereof.
HK13110275.0A 2010-08-05 2011-08-05 Combination of a pyrroloquinoline compound and an aminoglycodise antimicrobial agent HK1183615B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1013207.4 2010-08-05

Publications (2)

Publication Number Publication Date
HK1183615A HK1183615A (en) 2014-01-03
HK1183615B true HK1183615B (en) 2022-09-16

Family

ID=

Similar Documents

Publication Publication Date Title
US9549965B2 (en) Pharmaceutical composition for treating a microbial infection
US8940723B2 (en) Combination of a pyrroloquinoline compound and a beta-lactam antimicrobial agent, mupirocin or chlorhexidine
CA2794570C (en) Novel combination and use
EP2600868B1 (en) Combination of a pyrroloquinoline compound and an aminoglycodise antimicrobial agent
WO2018162928A1 (en) Method for restoring efficacy of an antibacterial agent
HK1183615B (en) Combination of a pyrroloquinoline compound and an aminoglycodise antimicrobial agent
HK1183615A (en) Combination of a pyrroloquinoline compound and an aminoglycodise antimicrobial agent
GB2589286A (en) Method
HK1183616B (en) Combination of a pyrroloquinoline compound and a beta-lactam antimicrobial agent, mupirocin or chlorhexidine
HK1183616A (en) Combination of a pyrroloquinoline compound and a beta-lactam antimicrobial agent, mupirocin or chlorhexidine